BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34978466)

  • 1. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.
    Patel HV; Srivastava A; Kim S; Patel HD; Pierorazio PM; Bagrodia A; Masterson TA; Ghodoussipour SB; Kim IY; Singer EA; Jang TL
    J Urol; 2022 May; 207(5):1057-1066. PubMed ID: 34978466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.
    Bhanvadia RR; Rodriguez J; Bagrodia A; Eggener SE
    BJU Int; 2019 Nov; 124(5):792-800. PubMed ID: 31054211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer.
    Pearce SM; Golan S; Gorin MA; Luckenbaugh AN; Williams SB; Ward JF; Montgomery JS; Hafez KS; Weizer AZ; Pierorazio PM; Allaf ME; Eggener SE
    Eur Urol; 2017 Mar; 71(3):476-482. PubMed ID: 27234998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
    Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
    Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
    Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
    Stepanian S; Patel M; Porter J
    Eur Urol; 2016 Oct; 70(4):661-667. PubMed ID: 27068395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
    Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
    Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
    Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
    J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
    Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
    Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
    Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
    Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort.
    Taylor J; Becher E; Wysock JS; Lenis AT; Litwin MS; Jipp J; Langenstroer P; Johnson S; Bjurlin MA; Tan HJ; Lane BR; Huang WC
    Eur Urol Focus; 2021 Nov; 7(6):1403-1408. PubMed ID: 32682794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
    Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
    Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors.
    Abdel-Aziz KF; Anderson JK; Svatek R; Margulis V; Sagalowsky AI; Cadeddu JA
    J Endourol; 2006 Sep; 20(9):627-31. PubMed ID: 16999613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
    Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
    Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.